Skip to content

Released Mar 16, 2017, after the close

10-K filed Mar 16, 2017, 75 days after period end · 0001564590-17-004614

Q4 2016 · 10-K
Revenue$1.03M−4.6% vs Q4 2015+0.1% vs Q3 2016
Net Income-$7.94MN/M vs Q4 2015N/M vs Q3 2016
EPS Diluted-$0.21N/M vs Q4 2015N/M vs Q3 2016
Operating Incomederived-$7,654,000N/M
Operating Cash Flowderived-$7,551,000N/M
Free Cash Flowderived-$7,591,000N/M
Margins · derived
Operating margin-745.3%−102.9 pt vs Q4 2015
Net margin-773.1%−81.1 pt vs Q4 2015

What the release said

No earnings release is on file for this quarter. Its figures came with the 10-K.

Same quarter

MetricQ4 2016Q4 2015Q4 2014Q4 2013
Revenue$1.03M$1.08M—$0.00
Net Income-$7.94M-$7.45M-$6.23M-$5.74M
EPS Diluted-$0.21-$0.26-$0.30-$0.29

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Fate Therapeutics Inc · CIK 1434316 · Engraved from SEC EDGAR